



Atty. Docket No.: 9000/2083

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Zoghbi, et. al.  
Serial No.: 09/884,384  
Filed: June 19, 2001  
Entitled: Chaperone Suppression of  
Ataxin-1 Aggregation and  
Altered Subcellular Protease  
Localization Imply Protein  
Misfolding in SCA1

Examiner: Falk, A.M.

Group Art Unit: 1632

Conf. No.: 5033

**CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a**

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Mail Stop: Sequence, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Mark J. Fitzgerald

Name of Person Mailing

  
Signature of Person Mailing Paper

Mail Stop: Sequence  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO OFFICE ACTION**

Sir:

This is in Response to the Notice to Comply mailed with the office communication mailed on June 3, 2003 which states (i) this application clearly fails to comply with the requirements of 37 C.F.R. 1.821 – 1.825; (ii) this application does not contain, as a separate part of the disclosure on paper copy, a “sequence listing” as required by 37 C.F.R. 1.821(c); and (iii) a copy of the “sequence listing” in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

Submitted herewith is a copy of the “Sequence Listing” in paper form and computer readable form for the above-identified patent application as required by 37 C.F.R. §1.821(c) and a copy of the Sequence Listing in computer readable form as required by 37 C.F.R. §1.821(e). As required by 37 C.F.R. §1.821(f), Applicant’s Attorney hereby states that the content of the “Sequence Listing” in paper form and the computer


RECEIVED  
AUG 11 2003  
TECH CENTER 1600/2900

readable form of the "Sequence Listing" are the same and, as required by 37 C.F.R. §1.821(g), also states that the submission includes no new matter. Applicant respectfully requests entry of the sequence listing.

Respectfully submitted,

*Mark J. FitzGerald*  
*Reg. No. - 45,928 to*

Date: August 4, 2003

  
Name: Kathleen M. Williams  
Registration No.: 34,380  
Customer No.: 29933  
Palmer & Dodge LLP  
111 Huntington Avenue  
Boston, MA 02199-7613  
Tel: 617-239-0100

Attorney Docket No: 9000/2083 (Serial No.:09/884,384)

Inventor: Zoghbi et al.

Filed: June 19 2001

Sequence Listing and Preliminary Amendment

Page iv

### AMENDMENTS

#### In the specification:

Please insert the attached "Sequence Listing" (sheets 1/1 through 1/1), and comprising SEQ ID NOs: 1-2, into the above-referenced application.

Please replace the paragraph at page 17, lines 11 through 22, with the following paragraph:

Full-length human HDJ-2/HSDJ and HDJ-2/HSDJ mutants  $\Delta 250$  (deletion of aa 9-46) and  $\Delta 450$  (deletion of aa9-107)<sup>32</sup> were subcloned in frame into the pFLAG-CMV-2 vector (Kodak). The primers HDJ2-FOR (5'-aataagaatgcggccgcgatgggtgaagaacaacttac-3' (SEQ ID NO: 1)) and HDJ2-REV (5'-gaatttgctgaaccattccaggtc-3' (SEQ ID NO: 2)) were used to PCR amplify the 5' end of HDJ-2/HSDJ containing an inframe Not I site. The PCR product was cut with NotI and EcoRI and subcloned into pFLAG-CMV-2. This construct was digested with EcoRI and XbaI to insert the 3' HDJ-2/HSDJ EcoRI/XbaI sequence. The constructs were confirmed by DNA sequence analysis.